Skip to content

Evaluation of Auditory Mirror-therapy for Tinnitus

Evaluation of Auditory Mirror-therapy for Tinnitus

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05710172
Enrollment
56
Registered
2023-02-02
Start date
2022-10-04
Completion date
2026-01-20
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus

Brief summary

The investigators will evaluate the effects of wearing auditory mirror earmuffs on tinnitus and on audiometry.The auditory mirror earmuffs is a device that re-routes auditory input from the left side of the head to the right ear, and vice verse, thereby flipping the auditory input. This procedure is called Auditory Mirror Therapy (AMT).

Detailed description

The goal of this study is to determine efficacy of a 21 day, 3 hours per day intervention of auditory mirror therapy (AMT) for chronic tinnitus. Hypothesis: AMT, as contrasted to a sham device, will significantly reduce symptom ratings on the Tinnitus Functional Index (TFI) scale. Along with TFI, additional measures will be collected every two days throughout the intervention; Tinnitus Handicap Index, Visual Analogue Scale, Minimum Masking Level (MML) and Residual Inhibition (RI), and Auditory Mirror Therapy Questionnaire.

Interventions

DEVICEAuditory Mirror Therapy

21 days, up to 3 hours per day intervention

Sponsors

Spaulding Rehabilitation Hospital
Lead SponsorOTHER
Harvard University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Concealment of treatment allocation is not possible

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male or Female * Ages 18-80 years old * Chronic Tinnitus (\> 3months)

Exclusion criteria

* Use of hearing aids * No history of significant drug or alcohol use * No history of debilitating neurological or psychiatric illnesses * No current or past history of balance-, vertigo- and/or vestibular- symptoms including Ménières disease

Design outcomes

Primary

MeasureTime frameDescription
Change in Tinnitus Functional Index (TFI)3 weeksThe Tinnitus Functional Index (TFI) is a 25-item questionnaire measuring tinnitus severity on a 0-100 scale. Scores are calculated by averaging item responses and scaling to 0-100, where higher scores signify greater distress. The change in TFI score between baseline and follow up is reported, with negative numbers indicating a decrease in tinnitus severity.

Secondary

MeasureTime frameDescription
Change in Tinnitus Handicap Inventory (THI)3 weeksa brief and psychometrically robust self-report measure used to quantify the impact of tinnitus on daily living.
Change in Visual Analogue Scale (VAS)3 weeksScale from 0 to 100 for tinnitus awareness, loudness and annoyance, on separate VAS. VAS loudness and annoyance are valid and effective measurements for capturing reductions in tinnitus severity in patients with chronic tinnitus
Change in Minimum Masking Level (MML) and Residual Inhibition (RI)3 weeksMML is defined as the lowest tone intensity level required to cover or mask and individual's tinnitus. Correspondingly, the RI is considered the temporary decrease of tinnitus after a prolonged acoustic stimulation.

Countries

United States

Baseline characteristics

Characteristic
Age, Continuous53 years
STANDARD_DEVIATION 14
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
47 Participants
Region of Enrollment
United States
56 participants
Sex: Female, Male
Female
23 Participants
Sex: Female, Male
Male
17 Participants
Tinnitus functional index40.8 units on a scale
STANDARD_DEVIATION 19.5

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 330 / 23
other
Total, other adverse events
0 / 330 / 23
serious
Total, serious adverse events
0 / 330 / 23

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026